Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer

Toxicologic Pathology

Volumn 38, Issue 1, 2010, Pages 88-95

  Bennett, Christina N ^a   Green, Jeffrey E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Genomics; Mammary cancer; Mouse models; Preclinical testing

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; BEXAROTENE; BRCA1 PROTEIN; CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HISTONE DEACETYLASE INHIBITOR; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHA 68032; PICROPODOPHYLLIN; PROGESTERONE RECEPTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; TARIQUIDAR; TRANSCRIPTOME; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE REGULATION; CHROMOSOME REARRANGEMENT; DNA REPAIR; DNA REPLICATION; DRUG TARGETING; GENE DUPLICATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE INACTIVATION; GENE NUMBER; GENE TARGETING; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ANIMAL; DISEASE MODEL; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC ENGINEERING; GENETICS; METHODOLOGY; MOUSE;

ANIMALIA;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION PROFILING; GENETIC ENGINEERING; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE;

EID: 77952299744     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623309357074     Document Type: Review

References (48)

1. Abba, M. C., Hu, Y., Levy, C. C., Gaddis, S., Kittrell, F. S., Hill, J., Bissonnette, R. P., Brown, P. H., Medina, D., and Aldaz, C. M. (2009). Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model. Cancer Prev Res (Phila Pa) 2, 175-184
2. Adelaide, J., Finetti, P., Bekhouche, I., Repellini, L., Geneix, J., Sircoulomb, F., Charafe-Jauffret, E., Cervera, N., Desplans, J., Parzy, D., Schoenmakers, E., Viens, P., Jacquemier, J., Birnbaum, D., Bertucci, F., and Chaffanet, M. (2007). Integrated profiling of basal and luminal breast cancers. Cancer Res 67, 11565-11575
3. Barkan, D., Montagna, C., Reid, T., and Green, J. E. (2004). Mammay Gland Cancer. In Mouse Models of Human Cancer (E. C. Holland, ed.) pp. 103-131 John Wiley & Sons, Inc., Hoboken, NJ.
4. Bennett, C. N., and Green, J. E. (2008). Unlocking the power of cross-species genomic analyses: Identification of evolutionarily conserved breast cancer networks and validation of preclinical models. Breast Cancer Res 10, 213.
5. Bergamaschi, A., Kim, Y. H., Wang, P., Sorlie, T., Hernandez-Boussard, T., Lonning, P. E., Tibshirani, R., Borresen-Dale, A. L., and Pollack, J. R. (2006). Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45, 1033-1040
6. Borowsky, A.D., Namba, R., Young, L. J.,Hunter, K.W.,Hodgson, J. G., Tepper, C. G., McGoldrick, E. T., Muller, W. J., Cardiff, R. D., and Gregg, J. P. (2005). Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis 22, 47-59.
7. Botrugno, O. A., Santoro, F., and Minucci, S. (2009). Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett 280, 134-144
8. Brodie, S. G., Xu, X., Qiao, W., Li, W. M., Cao, L., and Deng, C. X. (2001). Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 20, 7514-7523
9. Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., d'Assignies, M. S., Bergh, J., Lidereau, R., Ellis, P., Harris, A., Bogaerts, J., Therasse, P., Floore, A., Amakrane, M., Piette, F., Rutgers, E., Sotiriou, C., Cardoso, F., and Piccart, M. J. (2006). Validation and clinical utility of a 70-gene prognostic signature for women with nodenegative breast cancer. J Natl Cancer Inst 98, 1183-1192
10. Carpinelli, P., Ceruti, R., Giorgini, M. L., Cappella, P., Gianellini, L., Croci, V., Degrassi, A., Texido, G., Rocchetti, M., Vianello, P., Rusconi, L., Storici, P., Zugnoni, P., Arrigoni, C., Soncini, C., Alli, C., Patton, V., Marsiglio, A., Ballinari, D., Pesenti, E., Fancelli, D., and Moll, J. (2007). PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6, 3158-3168
11. Cho, R. W., Wang, X., Diehn, M., Shedden, K., Chen, G. Y., Sherlock, G., Gurney, A., Lewicki, J., and Clarke, M. F. (2008). Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 26, 364-371
12. Cleator, S., Heller, W., and Coombes, R. C. (2007). Triple-negative breast cancer: Therapeutic options. Lancet Oncol 8, 235-244
13. Deeb, K. K., Michalowska, A. M., Yoon, C. Y., Krummey, S. M., Hoenerhoff, M. J., Kavanaugh, C., Li, M. C., Demayo, F. J., Linnoila, I., Deng, C. X., Lee, E. Y., Medina, D., Shih, J. H., and Green, J. E. (2007). Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 67, 8065-8080
14. Dourdin, N., Schade, B., Lesurf, R., Hallett, M., Munn, R. J., Cardiff, R. D., and Muller, W. J. (2008). Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 68, 2122-2131
15. Dowsett, M., and Dunbier, A. K. (2008). Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14, 8019-8026
16. Fox, E., and Bates, S. E. (2007). Tariquidar (XR9576): A P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther 7, 447-459
17. Glas, A. M., Floore, A., Delahaye, L. J., Witteveen, A. T., Pover, R. C., Bakx, N., Lahti-Domenici, J. S., Bruinsma, T. J., Warmoes, M. O., Bernards, R., Wessels, L. F., and Van't Veer, L. J. (2006). Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7, 278.
18. Gouas, L., Goumy, C., Veronese, L., Tchirkov, A., and Vago, P. (2008). Gene dosage methods as diagnostic tools for the identification of chromosome abnormalities. Pathol Biol (Paris) 56, 345-353
19. Hay, T., Matthews, J. R., Pietzka, L., Lau, A., Cranston, A., Nygren, A. O.,Douglas-Jones, A., Smith, G. C., Martin, N. M., O'Connor, M., and Clarke, A. R. (2009). Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 69, 3850-3855
20. Hennessy, B. T., Gonzalez-Angulo, A. M., Stemke-Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J. S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., Liu, W., Stivers, D., Baggerly, K., Carey, M., Lluch, A., Monteagudo, C., He, X.,Weigman, V., Fan, C., Palazzo, J., Hortobagyi, G. N., Nolden, L. K., Wang, N. J., Valero, V., Gray, J. W., Perou, C. M., and Mills, G. B. (2009). Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69, 4116-4124
21. Herschkowitz, J. I., He, X., Fan, C., and Perou, C. M. (2008). The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10, R75.
22. Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., Backlund, M. G., Yin, Y., Khramtsov, A. I., Bastein, R., Quackenbush, J., Glazer, R. I., Brown, P. H., Green, J. E., Kopelovich, L., Furth, P. A., Palazzo, J. P., Olopade, O. I.,Bernard, P. S., Churchill, G. A.,Van Dyke,T., and Perou, C. M. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8, R76.
23. Hoenerhoff, M. J., Michalowski, A. M., Qiu, T. H., and Green, J. E. (2009). Chapter 4: Bioinformatics Approaches to the Analysis of the Transcriptome of Animal Models of Cancer. In Bioinformatics in Cancer and Cancer Therapy. Humana Press, Totowa, NJ.
24. Klinakis, A., Szabolcs, M., Chen, G.,Xuan, S., Hibshoosh, H., and Efstratiadis, A. (2009). Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A 106, 2359-2364
25. Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D., and Werb, Z. (2006). GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127, 1041-1055
26. Kuraguchi, M., Ohene-Baah, N. Y., Sonkin, D., Bronson, R. T., and Kucherlapati, R. (2009). Genetic mechanisms in Apc-mediated mammary tumorigenesis. PLoS Genet 5, e1000367.
27. Liu, M. L., Shibata, M. A., Von Lintig, F. C., Wang, W., Cassenaer, S., Boss, G. R., and Green, J. E. (2001). Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice. Oncogene 20, 2044-2049
28. Martinez, J. M., Sali, T., Okazaki, R., Anna, C., Hollingshead, M., Hose, C., Monks, A., Walker, N. J., Baek, S. J., and Eling, T. E. (2006). Druginduced expression of nonsteroidal anti-inflammatory drug-activated gene/ macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. J Pharmacol Exp Ther 318, 899-906.
29. Medina, D., Kittrell, F., Hill, J., Zhang, Y., Hilsenbeck, S. G., Bissonette, R., and Brown, P. H. (2009). Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila PA) 2, 168-174
30. Montagna, C., Lyu, M. S., Hunter, K., Lukes, L., Lowther, W., Reppert, T., Hissong, B., Weaver, Z., and Ried, T. (2003). The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. Cancer Res 63, 2179-2187
31. Pajic, M., Iyer, J. K., Kersbergen, A., van der Burg, E., Nygren, A. O., Jonkers, J., Borst, P., and Rottenberg, S. (2009). Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res 69, 6396-6404.
32. Ponzo, M. G., Lesurf, R., Petkiewicz, S., O'Malley, F. P., Pinnaduwage, D., Andrulis, I. L., Bull, S. B., Chughtai, N., Zuo, D., Souleimanova, M., Germain, D., Omeroglu, A., Cardiff, R. D., Hallett, M., and Park, M. (2009). Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 106, 12903-12908
33. Rakha, E. A., Aleskandarany, M., El-Sayed, M. E., Blamey, R.W., Elston, C.W., Ellis, I. O., and Lee, A. H. (2009). The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 45, 1780-1787
34. Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O., Zander, S. A., Derksen, P. W., de Bruin, M., Zevenhoven, J., Lau, A., Boulter, R., Cranston, A., O'Connor, M. J., Martin, N. M., Borst, P., and Jonkers, J. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 105, 17079-17084
35. Schade, B., Rao, T., Dourdin, N., Lesurf, R., Hallett, M., Cardiff, R. D., and Muller, W. J. (2009). PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis. J Biol Chem 284, 19018-19026
36. Shafee, N., Smith, C. R., Wei, S., Kim, Y., Mills, G. B., Hortobagyi, G. N., Stanbridge, E. J., and Lee, E. Y. (2008). Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 68, 3243-3250
37. Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T.,Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Thorsen, T., Quist, H., Matese, J. C., Brown, P. O., Botstein, D., Eystein Lonning, P., and Borresen-Dale, A. L. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98, 10869-10874
38. Strecker, T. E., Shen, Q., Zhang, Y., Hill, J. L., Li, Y., Wang, C., Kim, H. T., Gilmer, T.M., Sexton, K. R., Hilsenbeck, S. G., Osborne, C. K., and Brown, P. H. (2009). Effect of lapatinib on the development of estrogen receptornegative mammary tumors in mice. J Natl Cancer Inst 101, 107-113
39. Talmadge, J. E., Singh, R. K., Fidler, I. J., and Raz, A. (2007). Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 170, 793-804.
40. Turner, N. C., Lord, C. J., Iorns, E., Brough, R., Swift, S., Elliott, R., Rayter, S., Tutt, A. N., and Ashworth, A. (2008). A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 27, 1368-1377
41. van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536
42. van de Vijver, M. J., He, Y. D., van't Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C.,Marton, M. J., Parrish, M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L., van der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E. T., Friend, S. H., and Bernards, R. (2002). A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999-2009. (Pubitemid 35461656)
43. Varticovski, L., Hollingshead, M. G., Robles, A. I., Wu, X., Cherry, J., Munroe, D. J., Lukes, L., Anver, M. R., Carter, J. P., Borgel, S. D., Stotler, H., Bonomi, C. A., Nunez, N. P., Hursting, S. D., Qiao, W., Deng, C. X., Green, J. E., Hunter, K. W., Merlino, G., Steeg, P. S., Wakefield, L. M., and Barrett, J. C. (2007). Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res 13, 2168-2177
44. Vincent-Salomon, A., Gruel, N., Lucchesi, C., MacGrogan, G., Dendale, R., Sigal-Zafrani, B., Longy, M., Raynal, V., Pierron, G., de Mascarel, I., Taris, C., Stoppa-Lyonnet, D., Pierga, J. Y., Salmon, R., Sastre-Garau, X., Fourquet, A., Delattre, O., de Cremoux, P., and Aurias, A. (2007). Identification of typical medullary breast carcinoma as a genomic subgroup of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 9, R24.
45. Weaver, Z., Montagna, C., Xu, X., Howard, T., Gadina, M., Brodie, S. G., Deng, C. X., and Ried, T. (2002). Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene 21, 5097-5107.
46. Weaver, Z. A., McCormack, S. J., Liyanage, M., du Manoir, S., Coleman, A., Schrock, E., Dickson, R. B., and Ried, T. (1999). A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-cmyc transgenic mice. Genes Chromosomes Cancer 25, 251-260
47. Xu, X.,Wagner, K. U., Larson,D.,Weaver, Z., Li, C., Ried, T.,Hennighausen, L., Wynshaw-Boris, A., and Deng, C. X. (1999). Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22, 37-43.
48. Zhang, Y. W., Jones, T. L., Martin, S. E., Caplen, N. J., and Pommier, Y. (2009). Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J Biol Chem 284, 18085-18095